Incyte Corporation (INCY) News

INCY up and down but mostly up

David Gryska, Board Director, Chair of Audit Committee for MindMed increased his shares by 20% as of 8/23/24

See here: https://d1io3yog0oux5.cloudfront.net/sec/0000950170-24-100668/0000950170-24-100668.pdf

Executive Vice President and Chief Financial Officer of Incyte and sat on the board for Seagen, Inc. (NASDAQ: SGEN)... SGEN was bought out on December 14th, 2023 by Pfizer. It was a $43 billion deal.

If you are and INCY shareholder you should look into MNMD as well. Seems to be some good people connected to it.

Incy and Gern merger?

Ouch Ouch Ouch!
Incyte expects to generate revenue of $2.3 billion-$2.4 billion in U.S. sales alone, while Inrebic, which was acquired by Bristol after it bought Celgene in 2019, generated about $74 million in sales last year.

"We currently model that the company could get 30% market share, leading to revenue of approximately $390 million," said JMP Securities analyst Benjamin Reni.

nice chart but meaningless. Your first sentence says it all. Nothing has changed... no real pipeline, no dramatic news, nothing.
All value added over the last 6 months is being wiped out.
Will be going lower...

$60 most likely timeframe = 3 months to 2018 levels

Long or short INCYTE corp ? Move coming soon.

Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging trendlines , while also clearing the MA's resistance, a bounce of the bottom Bollinger Band is also anticipated.

Long or short INCYTE corp ? Move coming soon.

Fundamentally nothing much has changed in INCY recently but technically the stock is reaching a point of decision, is the correction? can we go higher? we are biased towards a break higher as indicators are improving while the price gets squeezed between they 100 and 200ma. The $82 region may be a good area to look for a long on a break from converging trendlines , while also clearing the MA's resistance, a bounce of the bottom Bollinger Band is also anticipated.

News: $INCY Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

24-week results demonstrate significant improvement in repigmentation of facial vitiligo lesions after treatment with ruxolitinib cream Data presented at the World Congress of Dermatology support the planned initiation of a pivotal Phase 3 program, for which preparations are current...

In case you are interested https://marketwirenews.com/news-releases/incyte-announces-positive-results-from-a-phase-2-study-of-ruxolitinib-cream-in-patients-with-vitiligo-8360862.html

News: $INCY Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in GRAVITAS-309, a pivotal Phase 3 trial for the first-line treatment of patients with chronic graft-versus-host disease (GVHD). The trial will evaluate the efficacy and safety of itacitinib, Incyte ...

Got this from https://marketwirenews.com/news-releases/incyte-announces-first-patient-treated-in-phase-3-clinical-trial-of-itacitinib-for-chronic-graft-versus-host-disease-7415414.html

INCY invest 65.08























normal chart




log chart

Never late and it is very promising

Not in, but wish would have bought several weeks ago when it dipped below $54.

I see Baker Bros picked up more shares, but now 2nd to Seattle Genetics in their portfolio.

You must of had a good run.

INCY

$INCY Incyte (NASDAQ:INCY)

2018 EPS Estimate: $0.41
2019 EPS Estimate: $2.44 (+495.1%)
Stock Price: $70.83
P/E Ratio: 110.7
Consensus Rating: Buy
Ratings Breakdown: 15 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $107.7839 (52.2% Upside)

Got lucky. Have been eyeing it more closely daily looking for a bottom before a run-up to data which came unfortunately prematurely. Also was watching NLNK. Brad Loncar (who I follow daily on Twitter) has both in his portfolio.

https://investorshub.advfn.com/Loncar-Cancer-Immunotherapy-ETF-(NASDAQ-CNCR)-CNCR-30772/

INCY

Fantastic great sale, Kyle Dennis and his 800 followers have bought this last month around 85.00 I'm sure there not happy, SHAME. Looks like ONCS will have a good chance for there app. Cheers

Sold @ $90.50 to take profits. Has moved nicely and possibly more upside, but market too volatile. (also was without power all weekend and it was off briefly a short time ago so don't want to not be able to trade).

INCY

Back in INCY @ $81.85. 52 week low. 2nd largest Baker Bros holding:



INCY

So glad sold @ $89.10 yesterday toward the EOD. Analyst's darling and Baker Bro big holding but not the street favorite. Thought they had good quarterly, but something is amiss. Has been a personal loss despite buying down.

INCY

How Incyte’s Jakafi Performed in 3Q17

By Mike Benson
Jan 9, 2018 | 9:23 AM

Incyte’s (INCY) oncology drug Jakafi (ruxolitinib) is approved for the treatment of myelofibrosis and polycythemia vera, two rare types of blood cancer.

Chart - 005 (click link below for chart)

The chart above compares the revenues for Jakafi over the last few quarters.

Jakafi and its importance
Incyte’s team sells the drug Jakafi in US markets, while the development and commercialization rights for Jakafi are licensed to Novartis (NVS) outside US markets. Novartis markets Jakafi under the brand name Jakavi outside US markets.

Jakafi is the first oral JAK inhibitor approved by the FDA, and it’s also the first drug approved by the FDA from Incyte’s portfolio. Jakafi’s patent rights for the composition of matter and the use of the drug are valid up to November 2026, and Incyte has also received an extension on these patents up to late 2027.

Jakafi’s revenue

In 3Q17, Jakafi saw revenue of $303.9 million compared to $223.9 million in 3Q16 resulting from its strong sales in US markets. For the first nine months of 2017 (which ended on September 30, 2017), Jakafi brought in revenue of $831.0 million. Analysts expect Jakafi’s sales to cross $1.0 billion in 2017.

Incyte reported royalty revenue of $41.3 million from Novartis for Jakavi sales in 3Q17. For the first nine months of 2017, its royalty revenue from Novartis was $104.0 million.

(click link below for chart)

The iShares S&P 500 Growth ETF (IVW) holds 15.5% of its total investments in healthcare companies. IVW holds 0.1% in Incyte, 1.7% in Johnson & Johnson (JNJ), 0.8% in Pfizer (PFE), and 0.6% in Amgen (AMGN).

6
Incyte’s Collaborations and Developments in 4Q17

By Mike Benson
Jan 9, 2018 | 9:23 AM

Incyte’s Jakafi and its collaborations
Incyte (INCY) has a well-established distribution network in the United States and sells its products Jakafi and Iclusig in the country through its own network.

However, outside US markets, the company has entered into an agreement with Novartis to develop and commercialize Jakafi. Novartis sells Jakafi under the name Jakavi, and Incyte receives royalties on Jakavi’s total sales.

Chart - 006 (click link below for chart)

The chart above compares Incyte’s royalty revenues and contract revenues over the last few quarters.

Recent developments
A few recent developments for Incyte include the following:

On December 10, 2017, Incyte released the 208-week (or four-year) follow-up data for its RESPONSE Study, a Phase 3 study evaluating Jakafi (ruxolitinib) for the treatment of patients with polycythemia vera who are resistant to hydroxyurea. The data show the durability of the response of Jakafi in treating polycythemia vera.
On November 15, 2017, Incyte announced the initiation of the RESET study, a double-blind, randomized, double-dummy pivotal study evaluating Jakafi in comparison to anagrelide in treating patients with essential thrombocythemia.

On October 31, 2017, Incyte announced the expansion of its collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN), to evaluate the efficacy and safety of Incyte’s epacadostat with AstraZeneca’s Imfinzi (durvalumab) for the treatment of patients with locally advanced non-small cell lung cancer.

On October 25, 2017, Incyte announced its collaboration with MacroGenics (MGNX) for MGA012, the investigational monoclonal antibody developed by MacroGenics. While Incyte received the exclusive worldwide rights for developing and commercializing MGA012 for all indications, MacroGenics retained the right to develop its pipeline in combination with MGA012.
________________________________________________
http://marketrealist.com/2018/01/incytes-collaborations-developments-4q17

INCY

Was thinking the same. Hope this will pass soon and buyers return for its value.

Still plenty of upside:

Consensus Rating: Buy
Consensus Rating Score: 2.79
Ratings Breakdown:
0 Sell Rating(s)
5 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)

Consensus Price Target: $141.59
Price Target Upside: 40.34% upside
_______________________________________
https://www.marketbeat.com/stocks/NASDAQ/INCY/

INCY

Herve made it clear that being taken over is not in Incyte's playbook. Their aspiration is to become a large international pharmaceutical. Celgene's acquisition of Impact Biomedicines seems to verify that. Hence maybe some of the downdraft in the stock price today.

CEO interview:

https://finance.yahoo.com/video/incyte-chief-discusses-companys-latest-193000812.html

INCY

FWIW:

Jim Cramer Advises His Viewers On Incyte And American Outdoor Brands

Craig Jones , Benzinga Staff Writer FOLLOW
January 08, 2018 7:17am Comments

Jim Cramer said on CNBC's "Mad Money" that Incyte Corporation
INCY is oversold. He would be a buyer of the stock.
_______________________________
https://www.benzinga.com/media/cnbc/18/01/10998447/jim-cramer-advises-his-viewers-on-incyte-and-american-outdoor-brands

I don't see over-sold on RSI nor Wm%(14). See over-bought on CCI(20)



INCY

Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms

WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Incyte Corporation (INCY) and Syros Pharmaceuticals, Inc. (SYRS) announced today that the companies have entered into a target discovery, research collaboration and option agreement. Under the agreement, Syros will use its proprietary gene control platform to identify novel therapeutic targets with a focus in myeloproliferative neoplasms (MPNs), and Incyte will receive options to obtain exclusive worldwide rights to intellectual property resulting from the collaboration for up to seven validated targets. Incyte will have exclusive worldwide rights to develop and commercialize any therapies under the collaboration that modulate those validated targets.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180108005822/en/

“The discovery and development of novel therapeutic approaches to treat MPNs is an important area of focus at Incyte,” said Reid Huber, Ph.D., Chief Scientific Officer of Incyte. “Through this collaboration, we believe that Syros’ gene control platform will allow us to advance our understanding of the underlying biology of MPNs and potentially uncover new molecular targets for drug discovery.”

“Our gene control platform has broad applicability across diseases,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “By working with Incyte, a leader in the discovery, development and commercialization of therapies for MPNs, we aim to leverage the promise of our platform to benefit patients with diseases beyond our current areas of focus. Meanwhile, we can continue advancing our own pipeline to achieve our long-term goal of building a fully integrated company with therapies that make a profound difference for patients.”

Terms of the Agreement

Under the terms of the agreement, Incyte will pay Syros $10 million upfront – including $2.5 million in cash and $7.5 million in prepaid research and development (R&D) – and purchase a total of $10 million in Syros common stock at $12.61 per share.

Should Incyte exercise all of its options under the agreement, Syros could receive up to $54 million from Incyte in target selection and option exercise fees. For products resulting from the collaboration against each of the up to seven selected and validated targets, Syros could receive up to $50 million in development and regulatory milestones, as well as up to $65 million in commercial milestones. Syros would also be eligible to receive low single-digit royalties on sales of products resulting from the collaboration.

The transaction is effective immediately.

About Incyte Corporation

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

About Syros Pharmaceuticals

Syros is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with advanced solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the collaboration will yield any validated targets, advance the understanding of MPNs or benefit patients; whether Incyte will exercise any of its options to exclusively license any such targets; and whether and when any of the target validation fee, options exercise fees, milestone payments or royalties under this collaboration will ever be paid by Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors; unanticipated delays; each company’s ability to compete against parties with greater financial or other resources; greater than expected expenses; and such other risks detailed from time to time in each company’s reports filed with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended September 30, 2017 filed by each company. Each party disclaims any intent or obligation to update these forward-looking statements.
__________________________________________________________

View source version on businesswire.com: http://www.businesswire.com/news/home/20180108005822/en/

INCY

As long as they don't turn out like KATX.

3 Promising Cancer Immunotherapies to Watch in 2018

Keith Speights, The Motley Fool
December 22, 2017

Any way you look at it, immunotherapies -- also known as immuno-oncology (I-O) drugs -- are hot commodities. Two of the top three cancer drugs projected to be the biggest winners in the next five years are immunotherapies: Bristol-Myers Squibb's (NYSE: BMY) Opdivo and Merck's (NYSE: MRK) Keytruda. Together, those two combined are on track to generate revenue topping $8 billion this year.

Immunotherapies work by spurring the body's immune system to fight cancer. The approach has gained such incredible traction in the research community that there are now over 2,000 immunotherapies in clinical-stage development or on the market. Out of that vast number, I think there are three especially promising cancer immunotherapies to watch in 2018.

Epacadostat

Incyte (NASDAQ: INCY) could have the most eagerly anticipated immunotherapy on its hands with epacadostat. Some types of cancer cells produce a protein called IDO (indoleamine 2,3-dioxygenase). This protein shuts down immune system T cells, which would normally attack the tumor. Epacadostat works by inhibiting production of IDO, therefore allowing the body's immune system to fight back against cancer.

Epacadostat's potential is so great that several major drugmakers have teamed up with Incyte to test the drug in combination with their own immunotherapies. Bristol-Myers Squibb and Incyte are evaluating a combination of Opdivo and epacadostat in late-stage studies targeting non-small cell lung cancer (NSCLC) and head and neck cancer. AstraZeneca and Incyte are also working together in testing a combination of Imfinzi and epacadostat in treating NSCLC.

But the most important study to watch next year is the late-stage Echo-301 study that Merck and Incyte are conducting to evaluate the potential of a Keytruda-epacadostat combo in treating melanoma. The two companies expect to announce results from this study in the first half of 2018. Echo-301 will be the first late-stage study to wrap up for epacadostat. If the results are positive, it could bode well for the many other combination studies that are in progress.
___________________

https://finance.yahoo.com/news/3-promising-cancer-immunotherapies-watch-110400872.html

INCY

Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte

Ken Kam , CONTRIBUTOR

Opinions expressed by Forbes Contributors are their own.

the best time to invest in biotech stocks is after the short-term speculators have sold.

After a very strong year, the biotech sector has suffered an 8% pullback over the past five weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro and Incyte.

Ken Kam: Your fund is up 38% this year, why do you think there is more room to grow in the sector this year?

Todd Hagopian: While the major biotechs have seen a relatively small pullback, some of the clinical stage, or one-drug companies, have pulled back extremely hard as the acquisition season has seemingly ended.

Nothing in the industry has changed, there will still be less regulation, more investment, and more innovation going forward.

The acquisitions will pick back up, and these premiums that have dissipated over the past couple months will return. This portion of the biotech sector is opening up some great bargains at the moment.


Kam: What did you look for when identifying your five biggest bargains in the sector for this article?

Hagopian: I looked at five sets of criteria:

Is the stock at least 20% off of its high?
Is the stock at least 30% off of their average target price?
Was there a revenue-based justification for pull-back?
Is an acquisition, or rumors of one, likely in the next year?
Is there is at least 50% growth potential in the next year?
Kam: Tell me about the five stocks you picked as this season’s biggest bargains?

Hagopian: The companies I chose are Alexion Pharmaceuticals (ALXN), Flexion Therapeutics (FLXN), Clovis Oncology (CLVS), Tesaro Inc (TSRO), and Incyte Corporation (INCY).

(content omitted)

Incyte

The stock is down based on buyout rumors that didn't materialize. However, this stock is part of the IDO inhibitor class, which is another growth area in immunotherapy. On top of that, INCY already has revenue of over $1B/year, offering immediate benefits to potential acquirers, beyond their valuable immunotherapy pipeline.

The bottom line is that this stock will likely be one of the next major acquisition targets in the industry, and should see $150 again over the next 12 months, offering a potential 50% return over that time period.

Kam: How are you using these five highlighted stocks in your portfolio?

Hagopian: As Biotechs have slipped over the past couple of months, I have retooled my portfolios to take advantage of what I view are the biggest bargains in the sector. These five stocks will make up approximately 35% to 45% of my portfolio moving forward.

My Take: Often, the best time to invest in biotech stocks is after the short-term speculators have sold. In the past five weeks, there have been no clinical failures with these five companies. What has changed is that the prospects for a large, quick, capital gain from a buyout decreased. Todd is confident that takeover speculation will be back and is using the pullback to buy these five stocks. I agree that the pullback has created a good entry point for those with investment horizons of more than one year.

Investing in biotech requires hours of research, combing through clinical trial data, looking at competitive drugs, analyzing the analysts, and tracking the ongoing catalysts of the stocks involved.

Todd has shown us how a good manager can apply intelligence, skill, and diligence so the outcome is not just a game of chance. He started his Biotech fund at Marketocracy in March, 2011. Since then, his returns have averaged 26.58%, which compares nicely to the S&P 500’s 12.87% return over the same period. Year-to-date, Todd’s Biotech fund is up 38.00%, versus 16.91% for the S&P, and 17.03% for the Nasdaq iShares Biotech ETF (IBB). Over the past five years, Todd has outperformed the #1 equity mutual fund manager in Morningstar's database.

Todd's Biotech fund is not a mutual fund. It is an investment option for clients of our separately managed account program. Here is Todd’s track record. For a full review of his 20+ articles on the market, please visit his profile. For information about investing with Todd, click here.
________________________________________
https://www.forbes.com/sites/kenkam/2017/11/28/biotech-pullback-makes-bargains-out-of-alexion-flexion-clovis-tesaro-and-incyte/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo#714ac7ed333d

INCY

In Incyte for the 1st time @ $99.25. Too high as the impact of RBC downgrade was more than anticipated. Baker Bro 2nd largest holding, in Zacks Biotech portfolio, and Brad Lancor's Cancer ETF -- much potential.

Analysts' Consensus Rating for Incyte Corporation (NASDAQ:INCY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 17 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating: Buy (Score: 2.81)
Consensus Price Target: $145.63 (47.18% upside)

https://www.marketbeat.com/stocks/NASDAQ/INCY/

INCY

https://seekingalpha.com/article/4124190-bristol-myers-squibb-brings-ace-card-midst-ido-inhibitor-battle

I have seen no evidence to support that drawn conclusion.

Perhaps INCY negotiated the MGNX/INCY deal to provide potential for a 2nd, alternative[or even improved] therapy candidate. Seems many I-O companies are conducting many 100s of trials with that priority in mind.

As a long-time INCY SH, I have not followed its PRs or clinical trials closely enough to draw a conclusion, one way or another.

INCY’s own PD-1 candidate (#msg-116696022) is apparently dead.

MGNX/INCY deal is + for both, so far today.

Not so surprising....One expects a fairly high failure rate in clinical trials,
though if they are just saving face, it'd be disheartening.

They stopped some trials:

The “slow recruitment” explanation given in today’s PR is clearly BS. https://t.co/digCGerNm1 pic.twitter.com/JsTIt7ZbTN— Ozgur Ogut (@Ogut_Ozgur) August 1, 2017
Confirmed in today’s PR. https://t.co/T60YAYM9uB is indispensable. https://t.co/XdVRArWVAH— Ozgur Ogut (@Ogut_Ozgur) August 1, 2017

Let's see here; We've got a pipeline full of promising candidates and a multitude of trials in progress....Revenues are up by 30 some %....
and the PPS drops 3.5%....Huh?
I'm in for the long haul. Looks very good.

http://www.mdedge.com/rheumatologynews/article/104503/rheumatoid-arthritis/baricitinib-shows-encouraging-phase-iii-results

There were four cases of malignancy reported in the baricitinib group and none in the adalimumab group in weeks 0-24. Two deaths were reported in the baricitinib group and none in the other two groups.


FDA must be focusing along the lines of this safety signal. Otherwise, this drug should have been a clear cut approval. We're back to the risk-averse FDA.

JMHO

FDA CRL on INCY/LLY data re med for RA is cause of today' s share price decline in both.

Baker Brothers selling all or a big chunk of their holdings:
http://services.corporate-ir.net/SEC/Document.Service?id=P3VybD1hSFIwY0RvdkwyRndhUzUwWlc1cmQybDZZWEprTG1OdmJTOWtiM2R1Ykc5aFpDNXdhSEEvWVdOMGFXOXVQVkJFUmlacGNHRm5aVDB4TVRRMk1UYzROU1p6ZFdKemFXUTlOVGM9JnR5cGU9MiZmbj1JbmN5dGVDb3Jwb3JhdGlvbl80MjRCN18yMDE3MDMxMC5wZGY=

We join the S&P 500, which means index funds pick us up, i think.
Also
Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania

they will partner w/ ?

This 10yr DCF valuation analyses implies Incyte $INCY is 5% undervalued... earnings Tuesday:

DCF Analysis

(Good news for INCY)—GILD’s Momelotinib goes 1-for-2 in SIMPLIFY/1-2 trials:

#msg-126609986.

What's going on today??

Incyte Corp fundamental analysis highlights shares are ~15% overvalued before earnings: Fair Value

Hello!? Hello?!

Anyone here?

INCY about to take off.

Just wanted to be the 1st to post that

Watching this closely now.

INCY 10 MINUTES

Cowen and Jefferis are out with reports defending the stock. suggesting the data from the presentation are not bad and this reaction is unjustified. I guess we were priced for perfection but no worries will come back.

44% swing in one week. Crazy!

$INCY recent news/filings

bullish
close > 1 and average volume > 100k
consolidation breakout
bullish engulfing candlestick

## source: finance.yahoo.com

Tue, 25 Aug 2015 20:36:07 GMT ~ INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits


read full: http://biz.yahoo.com/e/150825/incy8-k.html
*********************************************************

Tue, 25 Aug 2015 13:29:06 GMT ~ Top 10 Funds & Stocks at Risk of Being Squeezed in Market Turmoil


read full: http://finance.yahoo.com/tumblr/blog-top-10-funds-at-risk-of-being-squeezed-in-market-132924751.html
*********************************************************

Fri, 21 Aug 2015 13:28:14 GMT ~ Incyte Named 7th Most Innovative Company in the World by Forbes Magazine

[at noodls] - WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 21, 2015-- Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, ...

read full: http://www.noodls.com/view/253D056A8511683A9BEDCCEB1402A81AB929271F
*********************************************************

Fri, 21 Aug 2015 13:00:00 GMT ~ Incyte Named 7th Most Innovative Company in the World by Forbes Magazine

[Business Wire] - Incyte Corporation , a biopharmaceutical company focused on the discovery, development and commercialization of innovative proprietary therapeutics, today announced it has been ranked 7th on Forbes magazine’s 2015 list of the World’s Most Innovative Companies.

read full: http://finance.yahoo.com/news/incyte-named-7th-most-innovative-130000000.html
*********************************************************

Mon, 17 Aug 2015 12:02:00 GMT ~ Are the 3 Best-Performing Big-Cap Biotech Stocks of 2015 Still Worth Buying?


read full: http://www.fool.com/investing/general/2015/08/17/are-the-3-best-performing-big-cap-biotech-stocks-o.aspx?source=eogyholnk0000001
*********************************************************

$INCY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$INCY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/INCY/company-info
Ticker: $INCY
OTC Market Place: Not Available
CIK code: 0000879169
Company name: Incyte Corp.
Company website: http://www.incyte.com
Incorporated In: DE, USA
$INCY share structure

## source: otcmarkets.com

Market Value: $21,645,271,262 a/o Aug 28, 2015
Shares Outstanding: 180,482,542 a/o Jul 29, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$INCY extra dd links

Company name: Incyte Corp.
Company website: http://www.incyte.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/INCY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/INCY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=INCY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=INCY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=INCY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/news - http://finance.yahoo.com/q/h?s=INCY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/INCY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/INCY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/INCY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/INCY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/INCY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=INCY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/INCY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Incyte+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Incyte+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Incyte+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.incyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.incyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.incyte.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/INCY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/INCY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/INCY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/INCY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000879169&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/INCY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/INCY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=INCY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=INCY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=INCY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=INCY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=INCY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=INCY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=INCY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/INCY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=INCY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/INCY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=INCY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/INCY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/INCY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/INCY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/INCY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/INCY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/INCY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/INCY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=INCY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INCY



$INCY DD Notes ~ http://www.ddnotesmaker.com/INCY